{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:52:46Z","timestamp":1777675966247,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["journalofclinicalvirology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jcv.2014.04.012","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T02:31:32Z","timestamp":1398738692000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictive factors for adverse dermatological events during pegylated\/interferon alpha and ribavirin treatment for hepatitis C"],"prefix":"10.1016","volume":"60","author":[{"given":"Zhengxiao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingang","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiguo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengxiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanpu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2014.04.012_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2014.04.012_bib0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1155\/2009\/651952","article-title":"A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin","volume":"23","author":"Mistry","year":"2009","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cgh.2006.06.010","article-title":"Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy","volume":"5","author":"Berk","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000353160","article-title":"Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin","volume":"228","author":"Patrk","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.jcv.2014.04.012_bib0025","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1046\/j.1365-2133.2002.04897.x","article-title":"Diffuse inflammatory lesions in patients treated with interferon alpha and ribavirin for hepatitis C: a series of 20 patients","volume":"147","author":"Dereure","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0035","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases. AASLD Practice Guidelines. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2014.04.012_bib0040","first-page":"29","article-title":"Dermatological side effects","volume":"9","author":"L\u00fcbbe","year":"2008","journal-title":"Hot Top Viral Hepatitis"},{"key":"10.1016\/j.jcv.2014.04.012_bib0045","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archderm.135.8.1000","article-title":"High prevalence of cutaneous reactions to interferon alpha plus ribavirin combination therapy in patients with chronic hepatitis C virus","volume":"135","author":"Sookoian","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0050","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1365-2133.2005.06931.x","article-title":"Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases","volume":"153","author":"L\u00fcbbe","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MCG.0b013e318228b5f6","article-title":"A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C","volume":"46","author":"Tavakoli-Tabasi","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0060","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2014.04.012_bib0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamadermatol.2013.938","article-title":"Telaprevir-related dermatitis","volume":"149","author":"Roujeau","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0070","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0075","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.12539","article-title":"Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study","volume":"38","author":"Ogawa","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcv.2014.04.012_bib0080","article-title":"Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C","author":"Colombo","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jcv.2014.04.012_bib0085","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/apt.12560","article-title":"Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir","volume":"39","author":"Bichoupan","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcv.2014.04.012_bib0090","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2013.01.041","article-title":"Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis","volume":"58","author":"Ji","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0095","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bjid.2013.02.004","article-title":"Splenectomy prior to antiviral therapy in patients with hepatitis C virus related decompensated cirrhosis","volume":"17","author":"Ji","year":"2013","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jcv.2014.04.012_bib0100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1665-2681(19)31475-9","article-title":"Pegylated interferon, but not conventional interferon therapy induced severe skin lesions","volume":"11","author":"Li","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2014.04.012_bib0110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1468-3083.2012.04582.x","article-title":"Induction and exacerbation of psoriasis with interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases","volume":"27","author":"Afshar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/MEG.0b013e3282f1cc5d","article-title":"Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin","volume":"20","author":"Grossmann Sde","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/MEG.0b013e32818b27e5","article-title":"Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection","volume":"19","author":"Kartal","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2005.02.031","article-title":"Cutaneous necrosis after injection of polyethylene glycol-modified interferon alpha","volume":"53","author":"Dalmau","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1572-0241.2005.00323.x","article-title":"Tongue and skin hyperpigmentation during PEG-interferon-alpha\/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C","volume":"101","author":"Gurguta","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamadermatol.2013.1989","article-title":"Secondary hyperpigmentation during interferon alpha treatment for chronic hepatitis C virus infection","volume":"149","author":"Tsilika","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0140","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jhep.2012.02.004","article-title":"Severe cutaneous eruptions on telaprevir","volume":"57","author":"Chen","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2014.04.012_bib0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.mcg.0000225599.24072.46","article-title":"Severe allergic eczema due to pegylated alpha interferon may abate after switching to daily conventional alpha-interferon","volume":"41","author":"Veldt","year":"2007","journal-title":"J Clin Gastroenterol"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653214001450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653214001450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T23:39:44Z","timestamp":1565393984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653214001450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1386653214001450"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2014.04.012","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors for adverse dermatological events during pegylated\/interferon alpha and ribavirin treatment for hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2014.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}